Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xiaxing Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0094-8590; OpenAlex author ID A5101518550. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. LINC01137 facilitates pancreatic cancer stemness, chemoresistance and proliferation via the miR-7155-5p/KLF12/PI3K-Akt axis. Co-author DOI 10.1016/j.ijbiomac.2026.150088↗
  2. OSBPL10-CNBP axis mediates hypoxia-induced pancreatic cancer development. Last author DOI 10.1002/biof.2124↗
  3. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  4. A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresi… Co-author DOI 10.1038/s41421-023-00592-6↗
  5. Hypoxia-induced long non-coding RNA LINC00460 promotes p53 mediated proliferation and metastasis of pancreatic cancer by regulating the miR-4689/UBE2V1 axis an… Last author DOI 10.7150/ijms.87833↗
  6. The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating P… Co-author DOI 10.1002/ctm2.654↗
  7. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. Co-author DOI 10.1186/s13045-022-01348-7↗
  8. Identification of a lncRNA based signature for pancreatic cancer survival to predict immune landscape and potential therapeutic drugs. Co-author DOI 10.3389/fgene.2022.973444↗
  9. Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03985-1↗
  10. Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. Co-author DOI 10.1186/s13046-021-02097-0↗
  11. Construction and integrated analysis of a lncRNA-associated competing endogenous RNA network reveal functional lncRNAs in pancreatic cancer. Co-author DOI 10.21037/tcr.2020.04.03↗
  12. Corrigendum to "GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer" [Cancer Le… Co-author DOI 10.1016/j.canlet.2019.03.031↗
  13. PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis. Co-author DOI 10.2147/ott.s206039↗
  14. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  15. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … Co-author DOI 10.1186/s12943-017-0738-0↗
  16. GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.06.016↗
  17. The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy. Co-author DOI 10.3109/07357907.2015.1025794↗
  18. A case-control study indicates that the TRIB1 gene is associated with pancreatic cancer. Co-author DOI 10.4238/2014.august.7.30↗
  19. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Co-author DOI 10.1007/s00441-013-1711-x↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 13 shared papers, 2013–2024 · strength 1.18
  2. Chenghong Peng · 12 shared papers, 2013–2024 · strength 1.09
  3. Shuyu Zhai · 7 shared papers, 2019–2024 · strength 0.96
  4. Xiaomei Tang · 6 shared papers, 2018–2025 · strength 0.92
  5. Ronghao Zhang · 4 shared papers, 2023–2025 · strength 0.75
  6. Xinjing Wang · 5 shared papers, 2017–2025 · strength 0.74
  7. Yizhi Cao · 4 shared papers, 2022–2026 · strength 0.68
  8. Jiewei Lin · 4 shared papers, 2021–2023 · strength 0.56
  9. Hao Chen · 7 shared papers, 2013–2022 · strength 0.55
  10. Weishen Wang · 4 shared papers, 2017–2024 · strength 0.50
  11. Yishu Huang · 2 shared papers, 2023–2025 · strength 0.45
  12. Lingxi Jiang · 3 shared papers, 2021–2024 · strength 0.41
  13. Zhen Huo · 4 shared papers, 2017–2020 · strength 0.35
  14. Hao Chen · 3 shared papers, 2017–2024 · strength 0.35
  15. Baiyong Shen · 2 shared papers, 2022 · strength 0.34
  16. Xiongxiong Lu · 5 shared papers, 2013–2020 · strength 0.31
  17. Da Fu · 2 shared papers, 2022–2023 · strength 0.30
  18. Pengyi Liu · 2 shared papers, 2023–2024 · strength 0.30
  19. Chenlei Wen · 3 shared papers, 2017–2024 · strength 0.29
  20. Qian Zhan · 5 shared papers, 2013–2019 · strength 0.28
  21. Yihao Liu · 2 shared papers, 2022–2024 · strength 0.28
  22. Youwei Zhu · 2 shared papers, 2022–2024 · strength 0.28
  23. Gang Wei · 3 shared papers, 2016–2022 · strength 0.27
  24. Zengyu Feng · 1 shared paper, 2026 · strength 0.24
  25. Kexian Li · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.